Cargando…

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

SIMPLE SUMMARY: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) mutations usually benefit from targeted therapy treatment. Nonetheless, primary or acquired resistance mechanisms lead to treatment dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Canale, Matteo, Andrikou, Kalliopi, Priano, Ilaria, Cravero, Paola, Pasini, Luigi, Urbini, Milena, Delmonte, Angelo, Crinò, Lucio, Bronte, Giuseppe, Ulivi, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909869/
https://www.ncbi.nlm.nih.gov/pubmed/35267450
http://dx.doi.org/10.3390/cancers14051143
_version_ 1784666299213807616
author Canale, Matteo
Andrikou, Kalliopi
Priano, Ilaria
Cravero, Paola
Pasini, Luigi
Urbini, Milena
Delmonte, Angelo
Crinò, Lucio
Bronte, Giuseppe
Ulivi, Paola
author_facet Canale, Matteo
Andrikou, Kalliopi
Priano, Ilaria
Cravero, Paola
Pasini, Luigi
Urbini, Milena
Delmonte, Angelo
Crinò, Lucio
Bronte, Giuseppe
Ulivi, Paola
author_sort Canale, Matteo
collection PubMed
description SIMPLE SUMMARY: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) mutations usually benefit from targeted therapy treatment. Nonetheless, primary or acquired resistance mechanisms lead to treatment discontinuation and disease progression. Tumor protein 53 (TP53) mutations are the most common mutations in NSCLC, and several reports highlighted a role for these mutations in influencing prognosis and responsiveness to EGFR targeted therapy. In this review, we discuss the emerging data about the role of TP53 in predicting EGFR mutated NSCLC patients’ prognosis and responsiveness to targeted therapy. ABSTRACT: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Oncogene-addicted patients usually benefit from targeted therapy, but primary and acquired resistance mechanisms inevitably occur. Tumor protein 53 (TP53) gene is the most frequently mutated gene in cancer, including NSCLC. TP53 mutations are able to induce carcinogenesis, tumor development and resistance to therapy, influencing patient prognosis and responsiveness to therapy. TP53 mutants present in different forms, suggesting that different gene alterations confer specific acquired protein functions. In recent years, many associations between different TP53 mutations and responses to Epidermal Growth Factor Receptor (EGFR) targeted therapy in NSCLC patients have been found. In this review, we discuss the current landscape concerning the role of TP53 mutants to guide primary and acquired resistance to Tyrosine-Kinase Inhibitors (TKIs) EGFR-directed, investigating the possible mechanisms of TP53 mutants within the cellular compartments. We also discuss the role of the TP53 mutations in predicting the response to targeted therapy with EGFR-TKIs, as a possible biomarker to guide patient stratification for treatment.
format Online
Article
Text
id pubmed-8909869
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89098692022-03-11 The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy Canale, Matteo Andrikou, Kalliopi Priano, Ilaria Cravero, Paola Pasini, Luigi Urbini, Milena Delmonte, Angelo Crinò, Lucio Bronte, Giuseppe Ulivi, Paola Cancers (Basel) Review SIMPLE SUMMARY: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) mutations usually benefit from targeted therapy treatment. Nonetheless, primary or acquired resistance mechanisms lead to treatment discontinuation and disease progression. Tumor protein 53 (TP53) mutations are the most common mutations in NSCLC, and several reports highlighted a role for these mutations in influencing prognosis and responsiveness to EGFR targeted therapy. In this review, we discuss the emerging data about the role of TP53 in predicting EGFR mutated NSCLC patients’ prognosis and responsiveness to targeted therapy. ABSTRACT: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Oncogene-addicted patients usually benefit from targeted therapy, but primary and acquired resistance mechanisms inevitably occur. Tumor protein 53 (TP53) gene is the most frequently mutated gene in cancer, including NSCLC. TP53 mutations are able to induce carcinogenesis, tumor development and resistance to therapy, influencing patient prognosis and responsiveness to therapy. TP53 mutants present in different forms, suggesting that different gene alterations confer specific acquired protein functions. In recent years, many associations between different TP53 mutations and responses to Epidermal Growth Factor Receptor (EGFR) targeted therapy in NSCLC patients have been found. In this review, we discuss the current landscape concerning the role of TP53 mutants to guide primary and acquired resistance to Tyrosine-Kinase Inhibitors (TKIs) EGFR-directed, investigating the possible mechanisms of TP53 mutants within the cellular compartments. We also discuss the role of the TP53 mutations in predicting the response to targeted therapy with EGFR-TKIs, as a possible biomarker to guide patient stratification for treatment. MDPI 2022-02-23 /pmc/articles/PMC8909869/ /pubmed/35267450 http://dx.doi.org/10.3390/cancers14051143 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Canale, Matteo
Andrikou, Kalliopi
Priano, Ilaria
Cravero, Paola
Pasini, Luigi
Urbini, Milena
Delmonte, Angelo
Crinò, Lucio
Bronte, Giuseppe
Ulivi, Paola
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
title The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
title_full The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
title_fullStr The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
title_full_unstemmed The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
title_short The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
title_sort role of tp53 mutations in egfr-mutated non-small-cell lung cancer: clinical significance and implications for therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909869/
https://www.ncbi.nlm.nih.gov/pubmed/35267450
http://dx.doi.org/10.3390/cancers14051143
work_keys_str_mv AT canalematteo theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT andrikoukalliopi theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT prianoilaria theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT craveropaola theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT pasiniluigi theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT urbinimilena theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT delmonteangelo theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT crinolucio theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT brontegiuseppe theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT ulivipaola theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT canalematteo roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT andrikoukalliopi roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT prianoilaria roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT craveropaola roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT pasiniluigi roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT urbinimilena roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT delmonteangelo roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT crinolucio roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT brontegiuseppe roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy
AT ulivipaola roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy